Even though CDK4 and MDM2 amplification itself is a favorable prognostic factor for the survival of glioblastoma patients, a subgroup of FGFR3-fusion-positive patients with CDK4 and MDM2 amplifications had an even better overall survival rate than those with CDK4 and MDM2 amplification that were negative for FGFR3 fusions [81]. Here, MDM2 is linked to glioblastoma.